You searched for "floaters"

579 results found

Outcomes of ‘treat and extend’ for neovascular AMD

The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...

Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema

Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...

Intravitreal dexamethasone implant for diabetic macular oedema

The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...

First systematic review of COVID-19 colonisation of ocular tissues and secretions

The authors present the first systematic review summarising all the data regarding SARS-CoV-2 colonisation of ocular and periocular tissues and secretions. They reviewed all publications between December 2019 to April 2020 in the Cochrane Library, Medline, World of Science and...

Chemical injury

You are the on-call ophthalmologist. You receive a call from A&E regarding a 45-year-old man who sustained a chemical injury. He was mixing some cement, when a small amount entered his left eye. He was not wearing any protective goggles....

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

In conversation with Robert Johnston

Robert Johnston. What is your current role with Medisoft? Clinical Director, i.e. I head up the analysis for and design of Medisoft’s ophthalmology electronic medical records (EMR) product. I don’t program: all coding is done by Medisoft’s team of computer...

Ambient scribes: The silent revolution

Clinical practice is in the midst of a profound digital transformation with a new wave of technology gaining increasing prominence: ambient scribes. These AI-powered tools streamline documentation by converting doctor–patient conversations into structured clinical notes in near real time. Healthcare...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

Childhood glaucoma

When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This previously published article (2019) outlines the knowledge, techniques and approaches that offer...

VISION 2020 LINKS Programme and DR-NET World Sight Day Workshop

World Sight Day (WSD) was celebrated globally on 8 October 2020 [1]. From Australia and the Pacific to the Americas, via Asia, Africa and the Caribbean, awareness-raising and advocacy activities took place throughout the day, to focus attention on unnecessary...

The fragile p-value

Abdus Samad Ansari explores the limitation of the p-value and the application of the fragility index in clinical trials. Clinical trials and tribulations? The restoration of vision or more purely the gift of sight is an aspect of care that...